MNIA Cannis Inc (CE)

MNI Nutraceuticals Inc. (Pinksheets: MNIA) is pleased to announce that its Director of Research and Development, Dr. Tony Martin has been invited to do a seminar at the International Pharmaceutical Academy in Toronto, Ontario, Canada. International Pharmaceutical Academy (IPA) is a progressive organization dedicated to be the primary provider of Quality Education and Training for the Pharmaceutical, Medical Devices, Biologics, Cosmetics, and Allied Industries. The seminar hosted by Dr. Martin for Natural Health Products and Dietary Supplements is sponsored by Health Canada. Some of the participants at the International Pharmaceutical Academy include: Abbot Laboratories (NYSE: ABT), Millenium (NYSE: MLNM) and Wyeth (NYSE: WYE), along with Silliker, Jamieson Laboratories and Nutralab. �This is a great opportunity for Tony and MNI,� stated Mr. Harvey Panesar, President of MNI Nutraceuticals Inc. �To be in the company of such great progressive companies like Abbot and Wyeth is a great step for the credibility of our company,� continued Mr. Panesar. About MNI Nutraceuticals Inc. MNI Nutraceuticals Inc. is a company focused on providing a better health and lifestyle through natural products. MNI Nutraceuticals flagship products include Arthrizyme(TM) for general joint pain and Vital Slim, which is a proprietary formula for weight control and management. In the past few months the company has been working on an Infomercial on best-selling author Dr. Anthony Martin�s new book �Medical Crisis: Secrets Your Doctor won�t share with You�. This amazing new book provides Dr. Martin�s insights into the many things that an individual can eat and do in order to improve their health and wellness and that their medical doctor just does not have the time and resources to provide them. The book can be life-altering and even life-saving. For more information please visit: www.mninutra.com or www.medicalcrisisthebook.com. Safe Harbor Statement This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The risks and uncertainties that may affect the operations, performance development and results of the Company's business include but are not limited to fluctuations in financial results, availability and customer acceptance of our products and services, the impact of competitive products, services and pricing, general market trends and conditions.